Dr. Herman van Vlijmen
Brief Bio Dr. Herman van Vlijmen graduated with a Master’s degree in Bio-Pharmaceutical Sciences at Leiden University in The Netherlands and a PhD degree in Physical Chemistry at Harvard University. He worked 9 years at the biotech company Biogen in the Boston area, ultimately as Senior Scientist, in the computational design of small molecule drugs and protein therapeutics. In 2005 he joined Tibotec, a Johnson and Johnson company focusing on infectious diseases, as Director of Computational Drug Design. He is now Global Head of Computational Chemistry in the Discovery Sciences organization at Johnson & Johnson Innovative Medicine, located in Belgium. Since 2008 he is also Adjunct Professor of Computational Drug Discovery at Leiden University. Dr. Herman van Vlijmen has more than 70 publications and is inventor on 8 patents. Selected Publications Assessment of the Fragment Docking Program SEED. Goossens K, Wroblowski B, Langini C, van Vlijmen H, Caflisch A, De Winter H. J Chem Inf Model. 2020 Oct 26;60(10):4881-4893. doi: 10.1021/acs.jcim.0c00556. Epub 2020 Aug 31. Advances and Challenges in Computational Target Prediction. Sydow D, Burggraaff L, Szengel A, van Vlijmen HWT, IJzerman AP, van Westen GJP, Volkamer A. J Chem Inf Model. 2019 May 28;59(5):1728-1742. doi: 10.1021/acs.jcim.8b00832. Epub 2019 Feb 28. Predicting Activity Cliffs with Free-Energy Perturbation. Pérez-Benito L, Casajuana-Martin N, Jiménez-Rosés M, van Vlijmen H, Tresadern G. J Chem Theory Comput. 2019 Mar 12;15(3):1884-1895. doi: 10.1021/acs.jctc.8b01290. Epub 2019 Mar 1. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective. Schlessinger A, Welch MA, van Vlijmen H, Korzekwa K, Swaan PW, Matsson P. Clin Pharmacol Ther. 2018 Nov;104(5):818-835. doi: 10.1002/cpt.1174. Epub 2018 Aug 30. Computational chemistry at Janssen. van Vlijmen H, Desjarlais RL, Mirzadegan T. J Comput Aided Mol Des. 2017 Mar;31(3):267-273. doi: 10.1007/s10822-016-9998-9. Epub 2016 Dec 19. Quantitative prediction of selectivity between the A1 and A2A adenosine receptors. Burggraaff L, van Vlijmen HWT, IJzerman AP, van Westen GJP. J Cheminform. 2020 May 13;12(1):33. doi: 10.1186/s13321-020-00438-3. Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. Deflorian F, Perez-Benito L, Lenselink EB, Congreve M, van Vlijmen HWT, Mason JS, Graaf C, Tresadern G. J Chem Inf Model. 2020 Nov 23;60(11):5563-5579. doi: 10.1021/acs.jcim.0c00449. Epub 2020 Jul 6. |
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.
|